Current NonAdvSM treatments primarily target individual symptoms rather than the underlying disease mechanism. Blueprint Medicines' Ayvakit (avapritinib) is approved for advanced systemic mastocytosis but not for the nonadvanced form due to safety concerns, potentially giving bezuclastinib a clear path to becoming the first-in-class therapy specifically approved for NonAdvSM. With top-line results from the registration-directed portion expected in July 2025, Cogent appears well-positioned for a potential NDA filing by early 2026. Given the orphan disease status and demonstrated efficacy, bezuclastinib could command premium pricing if approved, potentially generating $300-500 million in peak annual sales for this indication alone.